Please assess the completion status of the following clinical trial:

Trial Title: Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Phase I (closed as of 5/30/02):~  * Histologically confirmed metastatic or unresectable solid tumor for which standard curative or palliative measures do not exist or are no longer effective~* Phase II:~  * Histologically confirmed metastatic or unresectable colorectal adenocarcinoma~* Measurable disease or assessable but nonmeasurable disease (including ascites, pleural/pericardial effusions, lymphangitis cutis/pulmonis, inflammatory breast disease, abdominal masses (not followed by CT scan/MRI), or cystic lesions)~  * Disease characterized only by elevated serum tumor marker allowed~* No known brain metastases~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* ECOG 0-2 OR~* Karnofsky 60-100%~Life expectancy:~* More than 3 months~Hematopoietic:~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm \^3~Hepatic:~* Bilirubin no greater than 1.5 mg/dL~* AST/ALT no greater than 2.5 times upper limit of normal~Renal:~* Creatinine normal OR~* Creatinine clearance at least 60 mL/min~Cardiovascular:~* No symptomatic congestive heart failure~* No unstable angina pectoris~* No cardiac arrhythmia~Other:~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No ongoing or active infection~* No peripheral neuropathy~* No prior allergic reactions to compounds of similar chemical or biologic composition to gefitinib or other study agents~* No other concurrent uncontrolled illness~* No psychiatric illness or social situation that would preclude study compliance~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No prior bone marrow or stem cell support with high-dose chemotherapy~* At least 24 hours since prior colony-stimulating growth factors~Chemotherapy:~* See Biologic therapy~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered~* No more than 3 prior chemotherapy regimens~Endocrine therapy:~* At least 2 weeks since prior hormonal therapy except megestrol for anorexia/cachexia~Radiotherapy:~* No prior pelvic or whole abdominal radiotherapy~* At least 4 weeks since other prior radiotherapy and recovered~Surgery:~* At least 4 weeks since prior major surgery (e.g., laparotomy) and recovered~Other:~* At least 4 weeks since prior investigational therapy~* No other concurrent investigational or commercial anticancer agents~* No concurrent combination antiretroviral therapy for HIV-positive patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).